Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

Clinical trial NCT04410978 · COMPLETED

Trial details

NCT number: NCT04410978
Sponsor: Sanofi
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Relapsing Multiple Sclerosis

Start date: 2020-06-30
Primary completion: 2024-07-15
Enrollment: 974

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.